ES2525411T3 - Células anucleadas diferenciadas y método para preparar las mismas - Google Patents

Células anucleadas diferenciadas y método para preparar las mismas Download PDF

Info

Publication number
ES2525411T3
ES2525411T3 ES09800871.7T ES09800871T ES2525411T3 ES 2525411 T3 ES2525411 T3 ES 2525411T3 ES 09800871 T ES09800871 T ES 09800871T ES 2525411 T3 ES2525411 T3 ES 2525411T3
Authority
ES
Spain
Prior art keywords
stem cells
cells
differentiated
prepare
transfection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09800871.7T
Other languages
English (en)
Inventor
Yosef Refaeli
Brian Curtis Turner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiga Biotechnologies Inc
Original Assignee
Taiga Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiga Biotechnologies Inc filed Critical Taiga Biotechnologies Inc
Application granted granted Critical
Publication of ES2525411T3 publication Critical patent/ES2525411T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Método de preparación de una pluralidad de células anucleadas que comprende: cultivar células madre inmortalizadas condicionalmente en presencia de un agente para inducir la diferenciación a eritrocitos; en el que el agente es IL-3 y EPO; en el que las células madre inmortalizadas condicionalmente se generaron mediante: a. transfección de una pluralidad de células madre con un primer vector que comprende: una secuencia de ácido nucleico que codifica para una molécula de MYC; b. transfección de las células madre con un segundo vector retroviral que comprende una secuencia de ácido nucleico que codifica para Bcl-2, Bcl-X, o una combinación de los mismos; y c. cultivo de las células madre con IL-3, IL-6, factor de células madre, trombopoyetina, ligando de Flt3, o una combinación de los mismos; y en el que la actividad de la molécula de MYC se ha suprimido antes de la diferenciación.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24

Claims (1)

  1. imagen1
    imagen2
ES09800871.7T 2008-07-21 2009-07-21 Células anucleadas diferenciadas y método para preparar las mismas Active ES2525411T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8241008P 2008-07-21 2008-07-21
US82410P 2008-07-21
PCT/US2009/051242 WO2010011644A2 (en) 2008-07-21 2009-07-21 Differentiated anucleated cells and method for preparing the same

Publications (1)

Publication Number Publication Date
ES2525411T3 true ES2525411T3 (es) 2014-12-22

Family

ID=41570826

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09800871.7T Active ES2525411T3 (es) 2008-07-21 2009-07-21 Células anucleadas diferenciadas y método para preparar las mismas

Country Status (11)

Country Link
US (1) US9169462B2 (es)
EP (2) EP2313496B1 (es)
JP (1) JP5762286B2 (es)
CN (2) CN103937749B (es)
AU (1) AU2009274172B2 (es)
CA (1) CA2731767C (es)
DK (1) DK2313496T3 (es)
ES (1) ES2525411T3 (es)
IL (1) IL209343A (es)
SG (1) SG193145A1 (es)
WO (1) WO2010011644A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101441843B1 (ko) * 2005-10-18 2014-09-17 내셔날 쥬이쉬 헬스 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및 사용 방법
EP2134852A4 (en) * 2007-03-13 2010-04-28 Nat Jewish Health PROCESS FOR THE PRODUCTION OF ANTIBODIES
EP2285832B1 (en) 2008-05-16 2020-08-26 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
ES2525411T3 (es) 2008-07-21 2014-12-22 Taiga Biotechnologies, Inc. Células anucleadas diferenciadas y método para preparar las mismas
EP2318435B1 (en) 2008-08-28 2015-12-23 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
WO2012043651A1 (ja) * 2010-09-30 2012-04-05 国立大学法人 熊本大学 ミエロイド系血液細胞の製造方法
KR102031386B1 (ko) * 2011-10-03 2019-10-11 닛산 가가쿠 가부시키가이샤 다능성 간세포로부터의 거핵구 및/또는 혈소판의 제조 방법
JP6285930B2 (ja) 2012-07-20 2018-02-28 タイガ バイオテクノロジーズ，インク． 造血コンパートメントの再構築及び自家再構築の増進
US9365825B2 (en) * 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10272115B2 (en) * 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
WO2014186508A1 (en) * 2013-05-15 2014-11-20 University Of Rechester Human extensively self-renewing erythroblasts (esre)
WO2015035235A1 (en) * 2013-09-06 2015-03-12 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Compositions and methods for increasing mesenchymal stromal cell migration to tumors
EP3224617A1 (en) * 2014-11-26 2017-10-04 Oxford University Innovation Limited Detection of acute myeloid leukaemia (aml) leukaemic stem cells (lsc)
WO2016149672A1 (en) 2015-03-18 2016-09-22 The Regents Of The University Of California Methods of preventing and reversing stem cell aging
US20190185820A1 (en) * 2016-08-26 2019-06-20 The Regents Of The University Of California Compositions and Methods for Inhibiting Stem Cell Aging
KR20190092472A (ko) 2016-12-02 2019-08-07 타이가 바이오테크놀로지스, 인코포레이티드 나노입자 제제
WO2018204762A1 (en) * 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Methods and compositions of modeling diseases with hematopoietic cell systems
FR3068366B1 (fr) * 2017-06-30 2023-11-24 Francais Du Sang Ets Procede de production de progeniteurs erythroides
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US12023357B2 (en) 2017-10-13 2024-07-02 Hackensack University Medical Center Rejuvenated aged hematopoietic stem cells and methods of use
US11708559B2 (en) 2017-10-27 2023-07-25 The Children's Hospital Of Philadelphia Engineered red blood cells having rare antigen phenotypes
CN108866005A (zh) * 2018-07-20 2018-11-23 东南大学 一种永生化人源神经干细胞系及其制备方法
WO2020210231A1 (en) 2019-04-08 2020-10-15 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
EP3969041A4 (en) 2019-05-14 2023-05-10 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION
CN113583965A (zh) * 2021-08-05 2021-11-02 大连干细胞与精准医学创新研究院 一种条件永生化人神经干细胞来源细胞膜纳米囊泡制剂及其制备方法和应用
WO2024010317A1 (ko) * 2022-07-04 2024-01-11 주식회사 아트블러드 유전자 과발현 조합을 이용한 적혈구 분화능이 우수한 불멸화 적혈구전구세포주 확립, 이의 제조방법 및 용도

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963489A (en) 1987-04-14 1990-10-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5849288A (en) 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
CA2135642C (en) 1992-08-21 1999-12-14 James G. Barsoum Tat-derived transport polypeptides
US5580760A (en) 1993-02-22 1996-12-03 The United States Of America As Represented By The Department Of Health And Human Services FUSE binding protein and cDNA therefor
EP0710283A4 (en) 1993-07-22 1997-07-02 Merck & Co Inc THE EXPRESSION OF HUMAN INTERLEUKIN-1-g (b) IN A TRANSGENIC ANIMAL
US5599705A (en) * 1993-11-16 1997-02-04 Cameron; Robert B. In vitro method for producing differentiated universally compatible mature human blood cells
US6713247B1 (en) 1996-09-03 2004-03-30 Signal Pharmaceuticials, Inc. Human CNS cell lines and methods of use therefor
EP0893493A3 (de) 1997-07-21 2002-12-04 Aventis Pharma Deutschland GmbH Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
DE69923550T2 (de) 1998-04-08 2006-02-16 Shionogi & Co., Ltd. Verfahren um Vorläuferzellen von Osteoklasten zu isolieren und ihre Differenzierung in Osteoklasten zu induzieren.
US6835567B1 (en) 1998-04-14 2004-12-28 Signal Pharmaceuticals, Inc. PNS cell lines and methods of use therefor
US6451558B1 (en) 1998-08-03 2002-09-17 Novartis Ag Genes in the control of hematopoiesis
US6913925B1 (en) 1998-08-12 2005-07-05 Signal Pharmaceuticals Llc Human mesencephalon cell lines and methods of use therefor
EP1157275A4 (en) 1999-02-28 2003-01-15 Univ Washington NOVEL TRANSDUCTION MOLECULES AND METHODS OF USING THE SAME
WO2000059540A1 (en) 1999-04-05 2000-10-12 Biocrystal Ltd. Assay kits and methods for immune complex-mediated activation involving shed antigens
US7135287B1 (en) 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US7311920B1 (en) 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
EP1103615A1 (en) 1999-11-25 2001-05-30 Universite De Geneve Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
US20010049393A1 (en) 1999-12-07 2001-12-06 Whitehead Institute For Biomedical Research Methods for defining MYC target genes and uses thereof
WO2001087058A1 (en) 2000-05-15 2001-11-22 Sonoko Habu Chimeric mouse having immunity constructed by using human cd34-positive cells and use thereof
US20020155127A1 (en) 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
US20070248618A1 (en) 2004-03-16 2007-10-25 Cohen David I Tat-Based vaccine Compositions and Methods of Making and Using Same
CA2423093C (en) * 2000-09-25 2013-09-17 Valentis, Inc. Improved system for regulation of transgene expression
EP1338198B1 (en) 2000-12-01 2007-11-28 Central Institute For Experimental Animals Method of constructing mouse suitable for the take, differentiation and proliferation of heterogenous cells, mouse constructed by this method and use of the mouse
WO2002057436A2 (en) 2001-01-19 2002-07-25 Gendel Limited Red blood cell from a transgenic animal as vehicle for polypeptide delivery
CN1240439C (zh) 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 肿瘤基因开关药物
EP1499180A4 (en) 2002-04-16 2006-09-13 Dana Farber Cancer Inst Inc CANCER MODELS
GB2387599B (en) 2002-04-17 2005-08-10 Jason Peter Brown Methods for producing antibodies
CA2483640A1 (en) 2002-05-16 2003-11-27 Bavarian Nordic A/S Fusion protein of hiv regulatory/accessory proteins
DK1408114T3 (da) 2002-10-11 2007-05-07 Imvision Gmbh Modulære antigen-transporter molekyler (MAT-molekyler) til modulation af immunreaktioner, tilhörende konstrukter, fremgangsmåder og anvendelser
WO2004035535A2 (en) * 2002-10-15 2004-04-29 Yeda Research And Development Co. Ltd. Erythrocyte differentiation factor, gene encoding same, and methods of use thereof
WO2005014785A2 (en) * 2003-06-18 2005-02-17 The George Washington University Conditionally-immortalized hematopoietic progenitor cell lines
CA2529752A1 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
US7705049B2 (en) 2004-01-21 2010-04-27 New York University Methods for treating non-melanoma cancers with PABA
GB0420963D0 (en) 2004-09-21 2004-10-20 Reneuron Ltd Hepatocyte
WO2006045064A2 (en) 2004-10-20 2006-04-27 Whitehead Institute For Biomedical Research Cultured hematopoietic stem cells and method for expansion and analysis thereof
WO2007067183A1 (en) 2005-12-09 2007-06-14 The Regents Of The University Of California Derivation of unlimited quantities of neutrophils or monocyte/dendritic cells
US20060156422A1 (en) 2005-01-10 2006-07-13 Medical Research Council Methods and compositions for the generation of antibodies
EP1876894A1 (en) 2005-04-26 2008-01-16 The Board of Trustees of the University of Illinois Nucleoside compounds and methods of use thereof
CA2620202C (en) 2005-08-26 2016-10-04 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
KR101441843B1 (ko) 2005-10-18 2014-09-17 내셔날 쥬이쉬 헬스 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및 사용 방법
EP1942948A4 (en) 2005-11-04 2010-03-03 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE NAV1.8 GENE
EP1792627A1 (en) 2005-12-05 2007-06-06 ImVisioN AG Modulation of the immune response by administration of intralymphatic transduction allergen (ITAG-)-molecules
EP2134852A4 (en) 2007-03-13 2010-04-28 Nat Jewish Health PROCESS FOR THE PRODUCTION OF ANTIBODIES
EP2214670A2 (en) 2007-11-02 2010-08-11 Taiga Biotechnologies, Inc. Compounds for treating abnormal cellular proliferation
SG188904A1 (en) 2008-03-17 2013-04-30 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
EP2285832B1 (en) 2008-05-16 2020-08-26 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
ES2525411T3 (es) 2008-07-21 2014-12-22 Taiga Biotechnologies, Inc. Células anucleadas diferenciadas y método para preparar las mismas
EP2318435B1 (en) 2008-08-28 2015-12-23 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc

Also Published As

Publication number Publication date
CA2731767C (en) 2016-12-06
AU2009274172A1 (en) 2010-01-28
IL209343A0 (en) 2011-01-31
EP2313496A4 (en) 2011-07-27
CN103937749A (zh) 2014-07-23
EP2313496A2 (en) 2011-04-27
WO2010011644A3 (en) 2010-04-08
SG193145A1 (en) 2013-09-30
AU2009274172B2 (en) 2015-08-13
EP2746387A1 (en) 2014-06-25
EP2313496B1 (en) 2014-10-08
CN102083970A (zh) 2011-06-01
IL209343A (en) 2015-02-26
JP5762286B2 (ja) 2015-08-12
DK2313496T3 (en) 2014-12-15
US20100047217A1 (en) 2010-02-25
CN103937749B (zh) 2018-04-17
WO2010011644A2 (en) 2010-01-28
CA2731767A1 (en) 2010-01-28
JP2011528567A (ja) 2011-11-24
CN102083970B (zh) 2014-10-22
US9169462B2 (en) 2015-10-27

Similar Documents

Publication Publication Date Title
ES2525411T3 (es) Células anucleadas diferenciadas y método para preparar las mismas
Hu et al. Opportunities for organoids as new models of aging
AR117697A2 (es) Medios de cultivo celular
CL2017000528A1 (es) Descubrimiento y producción de proteínas biológicas condicionalmente activas en las mismas células hospederas eucariotas de producción
BRPI0514641A (pt) cultivação das células tronco embriÈnica humana
AR090822A1 (es) Composiciones de cultivo de celulas y metodos para la produccion de polipeptidos
Chen et al. Glucose-6-Phosphate dehydrogenase, redox homeostasis and embryogenesis
BR112014017188A8 (pt) células hospedeiras com endossimbiontes artificiais
Cangkrama et al. Stem cells behind the barrier
BR112016028537A2 (pt) expansão e enxerto de células-tronco utilizando agonistas de notch 1 e/ou de notch 2
Schwach et al. Improved atrial differentiation of human pluripotent stem cells by activation of retinoic acid receptor alpha (RARα)
WO2015003160A3 (en) Hepatocytes in co-culture and uses thereof
Vélez et al. First metabolic insights into ex vivo Cryptosporidium parvum-infected bovine small intestinal explants studied under Physioxic conditions
US12385900B2 (en) Method for evaluating cytotoxicity of gas
Abreu et al. Metabolic changes during in vivo maturation of PSC-derived skeletal myogenic progenitors
ES2660763T3 (es) Sonda codificada genéticamente para la cuantificación de la concentración de piruvato y métodos de utilización del mismo
JP2012532592A5 (es)
US20200354674A1 (en) Methods of modulating cell phenotype by way of regulating the gaseous environment
BR112017007213A2 (pt) "processamento e utilização de fluidos do trato reprodutivo para melhorar a produção in vitro de embriões de mamífero"
Brown et al. The Integrated Stress Response Pathway Improves Aged Murine Muscle Stem Cell Activation and in vivo Regeneration
ES2527796B1 (es) Método para la cuantificación fluorimétrica de la enzina LDH en disolución
RU2010111327A (ru) Способ одномоментного определения длины теломер и количества делений популяции пролиферирующих клеток in vitro
Zeng et al. Complex I Governs Iron Levels in Bat Mitochondria to Couple Respiration with Lipid Metabolism
BR112018012223A2 (pt) membrana de camada única, métodos de fabrico de uma membrana e de preparação de um tecido biológico reconstruído, dispositivo de cultura celular, utilização in vitro da membrana, tecido biológico reconstruído e utilização de um tecido biológico reconstruído
Kelkar et al. Glucose levels impact the morphology and cell-type composition of human cerebral organoids